United Therapeutics Co. (NASDAQ:UTHR) Holdings Trimmed by Crawford Fund Management LLC

Crawford Fund Management LLC trimmed its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,692 shares of the biotechnology company's stock after selling 9,908 shares during the period. United Therapeutics makes up 1.8% of Crawford Fund Management LLC's investment portfolio, making the stock its 2nd largest holding. Crawford Fund Management LLC owned 0.05% of United Therapeutics worth $8,490,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. ClariVest Asset Management LLC lifted its position in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. USA Financial Formulas purchased a new position in United Therapeutics in the 3rd quarter worth about $33,000. Brooklyn Investment Group purchased a new position in United Therapeutics during the 3rd quarter valued at about $33,000. V Square Quantitative Management LLC purchased a new position in United Therapeutics during the 2nd quarter valued at about $30,000. Finally, Innealta Capital LLC bought a new stake in shares of United Therapeutics in the 2nd quarter valued at about $33,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of UTHR traded down $7.64 during mid-day trading on Friday, hitting $370.49. 211,323 shares of the company's stock were exchanged, compared to its average volume of 456,724. The company has a market cap of $16.54 billion, a price-to-earnings ratio of 16.37, a P/E/G ratio of 1.10 and a beta of 0.56. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The stock's 50-day moving average is $367.42 and its 200-day moving average is $334.45.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.38 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on UTHR shares. Jefferies Financial Group raised their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Bank of America decreased their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a research note on Thursday, August 1st. The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $964,983.42. This trade represents a 85.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 7,785 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The trade was a 74.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,227 shares of company stock valued at $47,398,820 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.